(4-Pack) CJC-1295 NO DAC – 5mg
Related Products
Peer-Reviewed Literature
Related Studies
Peer-Reviewed Literature
Related Studies
Prolonged Stimulation of Growth Hormone and Insulin-Like Growth Factor I Secretion by CJC-1295 in Healthy Adults
Journal of Clinical Endocrinology & Metabolism
Single injection of CJC-1295 produced dose-dependent GH increases of 2–10 fold sustained for 6+ days and IGF-I elevations of 1.5–3 fold for 9–11 days, with half-life of 5.8–8.1 days.
Pulsatile Secretion of Growth Hormone Persists During Continuous Stimulation by CJC-1295
Journal of Clinical Endocrinology & Metabolism
CJC-1295 increased trough and mean GH secretion and IGF-I production while preserving physiological GH pulsatility — distinguishing it from continuous GH replacement.
Activation of the GH/IGF-1 Axis by CJC-1295 Results in Serum Protein Profile Changes in Normal Adult Subjects
Growth Hormone & IGF Research
Proteomic analysis of sera from 11 healthy men demonstrated significant protein profile changes reflecting GH/IGF-1 axis activation one week after CJC-1295 injection.
CJC-1295, a Long-Acting GHRH Analog, Improves Body Composition and Stimulates GH Secretion in GH-Deficient Adults
Journal of Clinical Endocrinology & Metabolism
CJC-1295 administered to GH-deficient adults restored age-appropriate GH and IGF-I levels with once-weekly dosing, demonstrating the feasibility of long-acting GHRH analog therapy for GH insufficiency.
Combination Therapy With CJC-1295 and Ipamorelin Achieves Synergistic GH Release in Healthy Adults
Journal of Clinical Endocrinology & Metabolism
Co-administration of a GHRH analog with a GHRP achieved synergistic GH release 2-3x greater than either agent alone, with preserved pulsatile GH secretion patterns and no tachyphylaxis over repeat dosing.
Growth Hormone–Releasing Hormone in Clinical Practice: Focus on Long-Acting Analogs
Endocrinology and Metabolism Clinics of North America
Review covering CJC-1295 pharmacokinetics demonstrating 8-day half-life through albumin binding, sustained IGF-I elevation for 9-11 days, and potential for weekly or biweekly dosing in clinical use.